Medical Devices China

China Genetic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Genetic Testing Market Industry Trends and Forecast to 2034: Segmented by (Type, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.73 Bn Placeholder estimate
Estimate 2025 $1.95 Bn 8.8% of the global market
Projected 2034 $5.78 Bn 195.7% Adds $3.82 Bn over 9 forecast years
CAGR 2025–2034 12.8% Faster than 70% of 193 Medical Devices markets here
Key players 6 +1
  • China is 8.81% of the global market.
  • In APAC, the largest is China (this report) at $1.95 Bn.
  • Fastest growing: India at 13.6% a year.
  • China ranks 1st of 14 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$3.82 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Genetic Testing Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.73 Bn — —
2025 (base) $1.95 Bn +$221.7 Mn —
2026 (forecast) $2.20 Bn +$250.1 Mn +12.8%
2027 (forecast) $2.49 Bn +$282.1 Mn +27.2%
2028 (forecast) $2.80 Bn +$318.2 Mn +43.5%
2029 (forecast) $3.16 Bn +$359.0 Mn +61.9%
2030 (forecast) $3.57 Bn +$404.9 Mn +82.6%
2031 (forecast) $4.03 Bn +$456.8 Mn +106%
2032 (forecast) $4.54 Bn +$515.2 Mn +132.4%
2033 (forecast) $5.12 Bn +$581.2 Mn +162.1%
2034 (forecast) $5.78 Bn +$655.6 Mn +195.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Genetic Testing Market Analysis at a glance
Market size, 2025$1.95 Bn placeholder estimate
Forecast, 2034$5.78 Bn placeholder estimate
Growth (CAGR), 2025–203412.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, technology and end user (see all)
Key playersMyriad Genetics, Inc., Illumina, Inc., Natera, Invitae, Quest Diagnostics and 1 more (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Genetic Testing Market Analysis Executive Summary

Genetic testing reads a person's DNA to find inherited conditions, cancer risk, drug response and family links.

Key segments of the genetic testing market include type (Predictive Testing, Carrier Testing and Diagnostic Testing) and technology (PCR, Sequencing and Microarrays).

Bar chart: China Genetic Testing market size, 2024–2034, placeholder estimates. $1.73 Bn in 2024, $1.95 Bn in 2025 and $5.78 Bn in 2034, 12.8% CAGR.
China Genetic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Genetic Testing Market Dynamics

Market Growth Drivers

Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the genetic testing market.

Opportunity

Automation, smaller and cheaper instruments and growth in cancer and genetic testing give the genetic testing market room to grow.

Market Restraints

Costly instruments, a shortage of skilled lab staff and uneven payment for new tests hold back the genetic testing market.

Competitive Landscape for Genetic Testing Market in China

The genetic testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Genetic Testing Market in China

Genetic Testing in China: rules and payment

Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2]

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how genetic testing products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Genetic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Genetic Testing in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 6th highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 7th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 21 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Genetic Testing market in China?
Placeholder estimate: about $1.95 Bn in 2025, rising to about $5.78 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Genetic Testing market in China growing?
Placeholder estimate: about 12.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Genetic Testing market report cover?
The report splits the market by type (Predictive Testing, Carrier Testing, Diagnostic Testing, Newborn Screening and more), technology (PCR, Sequencing, Microarrays) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Genetic Testing market?
Key players include Myriad Genetics, Inc., Illumina, Inc., Natera, Invitae, Quest Diagnostics and Labcorp.
What is driving the Genetic Testing market?
Falling costs of testing, more demand for precision medicine and steady research spending by drug makers and labs are driving the genetic testing market.
Who regulates Genetic Testing in China?
Medical devices are regulated by the National Medical Products Administration (NMPA) and its provincial offices: class I devices are filed, and class II and III devices are registered. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
Back to Catalogue

Related Medical Devices reports in China

See all

Related on genomics and diagnostics and lab testing

See the topic